The DA strain and other members of the TO subgroup of Theiler's murine encephalomyelitis virus (TMEV) induce an early transient subclinical neuronal disease followed by a chronic progressive inflammatory demyelination, with persistence of the virus in the central nervous system (CNS) for the life of the mouse. Although TMEV-induced demyelinating disease (TMEV-IDD) is thought to be immune mediated, there is also evidence that supports a role for the virus in directly inducing demyelination. In order to clarify the function of DA virus genes, we generated a transgenic mouse that had tamoxifen-inducible expression of the DA L-coding region in oligodendrocytes (and Schwann cells), a cell type in which the virus is known to persist. Tamoxifen Theiler's murine encephalomyelitis virus (TMEV) is a member of the Theilovirus species of the Cardiovirus genus of the family of Picornaviridae (reviewed in reference 20). The Encephalomyocarditis virus species of the Cardiovirus genus includes the closely related encephalomyocarditis virus (EMCV) and mengovirus (MV). TMEV strains can be divided into two subgroups on the basis of their differing biologic properties. The GDVII strain and other members of the GDVII subgroup are highly virulent and produce a rapidly fatal neuronal infection in mice, with no persistence of the virus. In contrast, DA, BeAn, and other members of the less virulent TO subgroup induce an early transient subclinical neuronal disease followed by a chronic progressive inflammatory demyelination, with persistence of the virus in the central nervous system (CNS) for the life of the mouse. During TMEV-induced demyelinating disease (TMEV-IDD), relatively large amounts of the TMEV genome can be detected in oligodendrocytes and microglia, with little evidence of viral antigen or infectious virus, i.e., there is a restricted expression of DA viral proteins. TMEV-IDD is an excellent model of multiple sclerosis (MS) because of the similarity in the demyelinating pathologies and because the immune system appears to contribute to pathology in both disorders. Although TMEV-IDD is thought to be immune mediated, there is also evidence that supports a key role for the virus infection in demyelination: the virus persists throughout the demyelinating disease, primarily in oligodendrocytes and microglia; DA virus antigen and virions have been identified in oligodendrocytes (the CNS cells that make myelin), which have a "dying back" pathology (25, 26); and DA virus is known to cause demyelination in infected nude mice (29, 30) .
Theiler's murine encephalomyelitis virus (TMEV) is a member of the Theilovirus species of the Cardiovirus genus of the family of Picornaviridae (reviewed in reference 20). The Encephalomyocarditis virus species of the Cardiovirus genus includes the closely related encephalomyocarditis virus (EMCV) and mengovirus (MV). TMEV strains can be divided into two subgroups on the basis of their differing biologic properties. The GDVII strain and other members of the GDVII subgroup are highly virulent and produce a rapidly fatal neuronal infection in mice, with no persistence of the virus. In contrast, DA, BeAn, and other members of the less virulent TO subgroup induce an early transient subclinical neuronal disease followed by a chronic progressive inflammatory demyelination, with persistence of the virus in the central nervous system (CNS) for the life of the mouse. During TMEV-induced demyelinating disease (TMEV-IDD), relatively large amounts of the TMEV genome can be detected in oligodendrocytes and microglia, with little evidence of viral antigen or infectious virus, i.e., there is a restricted expression of DA viral proteins. TMEV-IDD is an excellent model of multiple sclerosis (MS) because of the similarity in the demyelinating pathologies and because the immune system appears to contribute to pathology in both disorders. Although TMEV-IDD is thought to be immune mediated, there is also evidence that supports a key role for the virus infection in demyelination: the virus persists throughout the demyelinating disease, primarily in oligodendrocytes and microglia; DA virus antigen and virions have been identified in oligodendrocytes (the CNS cells that make myelin), which have a "dying back" pathology (25, 26) ; and DA virus is known to cause demyelination in infected nude mice (29, 30) .
In order to clarify the functions of selected DA virus genes, we previously generated a mouse that expresses a subgenomic region of the virus as a transgene in myelin-synthesizing cellsoligodendrocytes and Schwann cells. We hypothesized that this transgenic mouse might show a phenotype of interest, thereby clarifying the functions of one or more of the expressed viral genes within myelinating cells. In order to control the time of transgene expression and to avoid tolerance in future immunological studies, we made the expression inducible. To achieve the intended site-specific and inducible expression, we prepared double transgenic mice, called DA/Cre mice, which carried a tamoxifen-inducible Cre recombinase protein under the control of the myelin proteolipid protein (PLP) transcriptional control element along with a subgenomic region of DA virus. The subgenomic region, which was preceded by a floxed transcription stop, included the DA 5Ј untranslated region (5Ј-UTR), the leader (L) protein-coding region, a region that encodes an out-of-frame protein (L*) important for TMEV-IDD (5, 34) , and P1 (the capsid-coding region) (1) . Interestingly, tamoxifen-treated young DA/Cre mice developed an acute progressive fatal paralysis with abnormalities of the oligodendrocytes and Schwann cells and demyelination but without significant lymphocytic infiltration. This result suggested that a gene(s) in this DA subgenomic region was capable of causing death of myelin-synthesizing cells without a clear contribution from the immune system. Additionally of note, treatment of DA/Cre mice at a later age led to transient weakness with persistent expression of the recombined transgene in the CNS, suggesting that this gene could persist in myelin-synthesizing cells, causing dysfunction without cell death, resembling the situation in DA virus-infected demyelinated mice.
We hypothesized that the pathogenic segment of the DA subgenomic transgene was the DA L-coding region because the L protein of cardioviruses is multifunctional, with pathogenic properties. L protein of cardioviruses has been shown to inhibit type I interferon (IFN) gene transcription (11, 35, 41) , inhibit nucleocytoplasmic transport and host cell translation (6, 23) , and regulate cell apoptosis (9, 27, 36) .
In order to clarify whether the DA L-coding region was the region within the DA subgenomic transgene that caused the white matter disease in DA/Cre mice, we generated another transgenic mouse that only expressed DA L downstream of the floxed transcription stop, i.e., the transgene lacked the DA 5Ј-UTR and P1. As in the case of the previous DA subgenomic region, DA L was inducibly expressed in myelin-synthesizing cells after tamoxifen treatment. We now report that this transgenic mouse, called DAL/Cre, showed a clinical and pathological picture similar to that for DA/Cre mice following early induction of DA L with tamoxifen, i.e., an acute progressive fatal paralysis with demyelination and without significant lymphocytic infiltration, indicating that the pathogenic region of the transgene in DA/Cre mice was the DA L-coding region. Of interest, there was evidence of death of myelin-synthesizing cells and apoptosis of cells in the peripheral nervous system (PNS) and CNS. Administration of a lower dose of tamoxifen caused dysfunction of myelin-synthesizing cells without cell death, similar to that seen with tamoxifen-treated older DA/ Cre mice. These results suggest that the expression of L plays a major role in the pathogenesis of TMEV-IDD. A virus infection and gene directly causing the death or dysfunction of oligodendrocytes may also underlie other virus-induced demyelinating diseases in which an immune-mediated mechanism has been stressed (19, 43) , as well as immune-mediated diseases in which virus involvement is not certain, such as MS (2, 10, 18) .
MATERIALS AND METHODS
Transgenic mice. A DAL transgene (Fig. 1A) that contains the chicken ␤-actin promoter followed by a floxed transcription terminator, then followed by the DA L-coding region, and finally followed by the globin poly(A) signal, was constructed in the following way. (i) The plasmid pBS246␤ loxP, which contained an efficient transcription terminator surrounded by loxP sites, was engineered as previously described (1) . (ii) The DA L-coding region fragment was amplified from a full-length infectious clone of DA, pDAFL3 (28) , using the following primers, which contained NheI enzyme cleavage sites as well as an overlapping Kozak sequence: forward, 5Ј-AGCAACCGCTAGCCACCATGGCTTGCAAA CATGGATAC-3Ј; reverse, 5Ј-AGCAACCGCTAGCTTACTGGGGTTCCAT GACAATATCG-3Ј. The PCR product was digested with NheI and cloned into SpeI-digested pBS246␤ loxP ϳ30 nucleotides downstream from the 3Ј-flanking loxP site. (iii) The transcription terminator sequence and DA L-coding region fragment within pBS246␤ loxP were removed from the resulting plasmid with NotI and inserted into a derivative of pCAGGS that contained a NotI site (1) . The resultant DAL transgene was linearized, purified by agarose gel electrophoresis, and used for pronuclear injection. Transgenic mice were produced by the University of Chicago Transgenic Mouse Core as described previously (1) . At 15 to 18 days, a tail biopsy specimen was taken to determine the genotype of the pups by using the following primers in a PCR: forward, 5Ј-ATGTGTGCCCTATTTGCAC AGC-3Ј; reverse, 5Ј-ACGAGCGGTAAGTCAGTCCATT-3Ј. Transgene-positive pups (founders) were saved and bred to make lines.
Transgenic mice carrying DA L were crossed with PLP/CreER T mice (7), which have the proteolipid protein (PLP) transcriptional control element driving expression in myelin-synthesizing cells of Cre recombinase protein fused to a mutated ligand-binding domain of the human estrogen receptor, thereby conferring tamoxifen inducibility. The presence of the PLP/CreER T transgene was detected as previously described (7), and the DAL transgene was detected by PCR using the above primers. Double transgenic mice, called DAL/Cre mice, were inoculated intraperitoneally with tamoxifen each day for 5 days for a total dose of tamoxifen that varied in different experiments between 15 and 50 g/g body weight. The tamoxifen solution was prepared by dissolving 50 mg of 4-hydroxytamoxifen (Sigma, St. Louis, MO) into 0.2 ml dimethyl sulfoxide (DMSO) and 0.3 ml ethanol (EtOH) and then adding 4.5 ml sunflower seed oil (Sigma) followed by a 20-min sonication. At the time of sacrifice, mice were anesthetized and in some cases perfused with phosphate-buffered saline (PBS) followed by 4% paraformaldehyde (pH 7.3).
RNA analysis. RNA was isolated from various tissues by extraction with TRIzol (Invitrogen, Carlsbad, CA), followed by purification using RNeasy (Qiagen, Valencia, CA). The RNA was subjected to reverse transcriptase PCR (RT-PCR) using random hexamers and Superscript III Platinum (Invitrogen) to generate cDNA. The cDNA was used in a PCR (Eppendorf Mastermix) with the same primers shown above, and the amplified products were analyzed by agarose gel electrophoresis.
Teased fiber preparation, histopathology, and electron microscopy. Following sacrifice, the brain, optic nerves, spinal cord, and sciatic nerve were collected, processed for light and electron microscopic examination with paraffin or Epon embedding, and sectioned using standard procedures. In some cases, the sciatic nerves were dissected and prepared for teased fiber analysis, as described previously (1) .
Immunohistochemical analysis. At various times after tamoxifen treatment, animals were sacrificed and tissues collected and processed for terminal deoxy- T and L transgenes is noted above the gel. 1862 and 1864 mice were sacrificed when moribund ϳ20 days after the last day of tamoxifen treatment, while 1830 and 1842 were sacrificed ϳ100 days after tamoxifen. 1849, which carried only the PLP/CreER T transgene, and 1870, an untreated double transgenic mouse, were sacrificed when ϳ150 days old. The predicted ϳ180-bp product of L mRNA was detected in the spinal cords (lanes 3, 5, 9, and 11), but not lungs from tamoxifen-treated double transgenic mice and not from lungs or sc from untreated nontransgenic or treated single transgenic mice.
nucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) assay (Millipore Corp., Billerica, MA) and immunohistochemical staining using rabbit anti-cleaved caspase-3 antibody (Cell Signaling Technology, Danvers, MA), antiIba1 antibody (Wako Pure Chemical Industries, Osaka, Japan), and anti-CD3 rat monoclonal antibody (17A2, sc-18843; Santa Cruz Biotechnology, Santa Cruz, CA) with an ABC Vectastain kit (Vector Laboratories, Burlingame, CA).
RESULTS
Double transgenic DAL/Cre mice were prepared as described in Materials and Methods. DAL/Cre mice contained the PLP/CreER T transgene along with the DA L-coding region under the control of the chicken ␤-actin promoter and downstream of a floxed transcription stop site. Cre is predicted to enter the nuclei of myelinating cells of tamoxifen-treated double transgenic mice and recombine out the transcription terminator upstream of the DA L-coding region, thereby allowing spatially and temporally controlled expression of DA L in myelin-synthesizing cells (Fig. 1A) .
Agarose gel electrophoresis of the amplified product of an RT-PCR of total RNA from the spinal cord of DAL/Cre mice treated at age 15 weeks with 25 g/g tamoxifen and sacrificed ϳ20 days later showed a band of the size predicted following Cre-induced recombination (Fig. 1B, lanes 3 and  5) ; no band was detected in RNA from nonneural tissue (Fig. 1B, lanes 4 and 6) . As in the case with DA/Cre mice, CNS tissues from surviving DAL/Cre mice that had been treated at age 12 or 16 weeks with 15 g/g tamoxifen had evidence of persistent expression of the recombined DA segment (Fig. 1B, lanes 9 and 11) for as long as 3 months (the longest time sampled), demonstrating that some cells expressing DA L had not died. In contrast, RT-PCR of lungs from these mice as well as CNS tissue from noninduced double transgenic mice and from tamoxifen-treated single transgenic mice showed no evidence of recombination after 30 cycles of amplification (Fig. 1B) .
Tamoxifen-treated double transgenic DAL/Cre mice develop weakness. The tamoxifen-treated DAL/Cre mice (Table 1) had a clinical and pathological phenotype similar to that of tamoxifen-treated DA/Cre mice (1). DAL/Cre mice that were 8 to 10 weeks of age and treated with 25 to 50 g/g of tamoxifen typically began to show weakness of their hind limbs 1 to 2 weeks after the last tamoxifen injection. This weakness progressed rapidly to involve the forelimbs. Animals with severe weakness had shallow respirations and usually became moribund within a week after the onset of signs, at which time they were euthanized.
In order to facilitate the survival of mice, we supported mice during their time of maximal weakness and also treated older DAL/Cre mice with a lower dose of tamoxifen. DAL/Cre mice that were 12 to 16 weeks of age and treated with 15 g/g of tamoxifen remained unaffected or tended to develop subtle weakness and weight loss, which generally appeared within 2 to 3 weeks of the last tamoxifen injection, and recovered over time. No weakness was observed in DAL/Cre mice that were not tamoxifen treated or in single transgenic mice that were tamoxifen treated.
Tamoxifen-treated double transgenic DAL/Cre mice that become paralyzed and die show demyelination with dysfunction or death of oligodendrocytes and Schwann cells. Moribund paralyzed tamoxifen-treated DAL/Cre mice were euthanized, and the sciatic nerves, optic nerves, brains, and spinal cords were processed for histological examination. Individual myelinated axons teased from the sciatic nerve showed prominent segmental demyelination ( Fig. 2A) . Epon-embedded sections of the sciatic nerve (Fig. 2B) confirmed the presence of demyelination of peripheral nerve axons seen in the teased fiber preparations: there was an increase in unmyelinated axons compared to results for tamoxifen-treated control mice, as well as abnormally thin myelinated axons (indicating remyelination) and degenerating Schwann cells (Fig. 2B) . Frequently surrounding the thinly myelinated axons were fully myelinated axons and normal-appearing Schwann cells, presumably because the recombination mediated by Cre is incomplete and random in removing DNA segments between loxP sites. Abnormalities of CNS myelin and oligodendrocytes were easiest to detect in the optic nerves. The optic nerves tended to have clusters of unmyelinated axons, abnormally thin myelinated sheaths of axons, and degenerating oligodendrocytes with ev- Fig. 2C and D) . Immunohistochemical studies showed a proliferation and infiltration of microglial cells in the sciatic nerves (Fig. 2E) , spinal cord white matter (Fig. 2G) , and optic nerves (Fig. 2I ) of DAL/Cre mice compared to controls (Fig. 2F, H , and J), with no evidence of T cell infiltration (data not shown).
Because L of BeAn, a TO subgroup strain closely related to DA, induces apoptosis of cultured BHK-21 cells (9), we TUNEL-stained PNS and CNS tissues for evidence of apoptosis. There was TUNEL staining of cells in the sciatic nerves (Fig. 3A) , spinal cords (Fig. 3B) , and optic nerves (Fig. 3C ) of weak DAL/Cre mice following tamoxifen treatment. Sections of these same tissues as well as nerve roots had evidence of activated caspase-3 immunostaining (Fig. 3D to G) , confirming the apoptosis. Of interest, the activated caspase-3 staining of nerves and nerve roots (Fig. 3E ) was more prominent than the staining of oligodendrocytes in the CNS white matter (Fig. 3F  and G) . In addition, the activated caspase-3 staining was more prominent than TUNEL staining. No TUNEL staining or activated caspase-3 immunostaining was seen in tissues from littermate controls (data not shown).
Surviving tamoxifen-treated DAL/Cre mice exhibit demyelination and microgliosis. At times, DAL/Cre mice that were treated with tamoxifen became weak and survived, especially when they were supported during the time of maximal weakness. These mice tended to have prominent abnormalities of the Schwann cells and myelin of the sciatic nerve (data not shown) that resembled findings in paralyzed moribund tamoxifen-treated mice ( Fig. 2A and B) . At times, robust white matter abnormalities were also present in the CNS. Figures 4C  and D, 5C and D, and 6 show sections from CNS tissues of two DAL/Cre mice that were treated with tamoxifen when 53 days of age, became paralyzed at 70 days of age, and were sacrificed when partly recovered at 96 days of age. There were prominent white matter abnormalities in the corpus callosum (Fig. 4C,  5C , and 6A) and optic nerve (Fig. 4D, 5D , and 6B and D), with demyelinated or thinly myelinated axons and degenerating oligodendrocytes. In addition, there were swollen dystrophic axons filled with mitochondria and lysosomes and, at times, surrounded by thin myelin (Fig. 4C and 6A) . The white matter abnormalities in the corpus callosum and optic nerve were more extensive than in the spinal cords (data not shown) of these mice. In addition, the CNS pathology in some of the mice that partly recovered from their initial paralysis was more prominent than the CNS pathology in mice that were treated with high doses of tamoxifen at a young age and sacrificed when paralyzed and moribund ( Fig. 2C and D) . The changes that were seen in these tamoxifen-treated DAL/Cre mice were not apparent in littermate controls (Fig. 4A and B and 5A and B) . DAL/Cre mice that were treated with a lower dose of tamoxifen (15 g/g) developed no disease or had subtle transient weakness. When these mice were sacrificed 3 months after tamoxifen treatment, Epon-embedded sections of the sciatic nerves showed no obvious pathology. Abnormalities of the optic nerve, however, were apparent, with an increase in nonmyelinated axons and abnormally thin myelin sheaths ( Fig. 7A  and B) . Iba1 immunohistochemical staining demonstrated that the optic nerve had an increase in activated microglia and macrophages (Fig. 7C ) compared to the optic nerves of littermate controls (Fig. 7D) . There was no TUNEL staining or activated caspase-3 staining of the sciatic nerves, spinal cords, or optic nerves (data not shown) of these tamoxifen-treated or control mice at this time. 
DISCUSSION
The DA strain and other members of the TO subgroup of TMEV produce a chronic inflammatory CNS demyelinating disease that is thought to be immune mediated; however, evidence also supports a key role for the virus in carrying out the demyelination (reviewed in reference 20). The relative contribution in TMEV-IDD of a direct virus-mediated oligodendrocyte dysfunction/lysis vis-à-vis immune-mediated demyelination remains unclear, as is the case with other demyelinating diseases (19, 43) , including MS (2, 10, 18) . In order to clarify the functions of selected DA virus genes, we made use of the Cre/loxP system to provide inducible and cell-type-specific expression of DA L in oligodendrocytes (and Schwann cells), a cell type in which DA virus is known to persist.
Our previous studies involved inducible expression of a DA subgenomic region (DA 5ЈUTRLL*P1) as a transgene in DA/Cre mice (1) . Induction of the transgene in myelinsynthesizing cells of young mice led to rapidly fatal paralysis with demyelination and abnormalities of oligodendrocytes and Schwann cells, but without significant T cell infiltrates. Mice that survived or mice that were treated with tamoxifen at a later age also had evidence of demyelination and remyelination when sacrificed. In order to delineate the pathogenic region within the DA5ЈUTRLL*P1 subgenomic segment, we prepared DAL/Cre mice, which express only the Recent studies have demonstrated that cardiovirus L protein has a number of activities that are likely to contribute to disease: inhibition of type I IFN gene transcription (11, 35, 41) , inhibition of cellular mRNA export from the nucleus leading to interference with translation (6, 23) , and regulation of apoptosis (9, 27, 36) . Recent in vitro studies have shown that transfection of an L expression construct of BeAn into BHK-21 cells leads to cell death and apoptosis (9) and that DA L is apoptotic in both BHK-21 and HeLa cells (36) . Apoptosis has been identified in varied neural cells in the CNS after TMEV infection of mice, both early after infection and during TMEV-IDD (3, 4, 33, 39) ; however, the TMEV gene responsible for the apoptosis in infected neural cells has not been identified. The present study is the first to demonstrate that expression of DA L causes apoptosis of cells in the PNS and CNS white matter of mice. We found greater caspase-3 staining than TUNEL staining of these cells, perhaps reflecting a failure to implement the full apoptotic machinery, as is the case in certain cultured cells infected with TMEV (36) . We presume that at least some of the apoptotic cells are Schwann cells and oligodendrocytes since L is expressed only in these cells and since there was electron microscopic evidence of degeneration of these cells (Fig. 2B and 6B to D) with what appeared to be apoptotic changes of the nucleus (Fig. 6C) ; however, we were unsuccessful in carrying out double label immunohistochemical studies, perhaps due to the inhibition of translation of cell type-specific markers caused by L.
It is of interest that animals supported during their acute weakness as well as older animals treated with a low dose of tamoxifen survived despite the continuing expression of DA L. We suspect that these mice survived because Cre recombinasemediated recombination occurred in a more limited number of myelin-synthesizing cells within an individual animal. Also of interest was the prolonged survival of myelin-synthesizing cells despite the continuing expression of L. We presume that these cells did not die despite continuing expression of L because only some of the multiple copies of the floxed transgene within an individual cell were recombined, resulting in lower levels of L expression in some cells, i.e., low levels of expression of DA L allowed a cell to survive (while high levels killed the cell).
Mice that became paralyzed following tamoxifen treatment but survived had evidence of demyelination of the corpus callosum and optic nerve with microgliosis (Fig. 4 to 6 and 7C) . Interestingly, despite the spatial restriction of DA L to myelinsynthesizing cells, tamoxifen-treated DAL/Cre mice had abundant evidence of swollen axons with dystrophic neurites filled with mitochondria and lysosomes ( Fig. 4C and 6A ). Our data, as well as those of the two recent studies (22, 38) that used transgenic mice identical or similar to the present one demonstrate that axonal damage can occur following a restricted oligodendrocyte injury in the absence of T cells. Axonal damage has been described in TMEV-IDD and MS, including the presence of dystrophic axons (15, 31) . The DAL/Cre mouse model may be of value in studies of demyelination and remy- The phenotype of DAL/Cre (and DA/Cre) mice (i.e., CNS demyelination with persistent expression of DA L in oligodendrocytes) resembled that seen in TMEV-IDD, in which demyelination is associated with persistence of the virus genome in oligodendrocytes (and microglia) and little production of infectious virus. The similar phenotypes indicate the potential importance of DA L to TMEV-IDD pathogenesis. Myelin protein synthesis may be disturbed during TMEV-IDD because of an inhibition by L of mRNA exit (6, 23) from the nuclei of oligodendrocytes and also because of suppression of host cell protein synthesis by type I IFN, which is present at a low level in the CNS of DA virus-infected chronically demyelinated mice (35) . There is presumably a balance between L and type I IFN expression, so that type I IFN inhibits the synthesis of viral proteins, including L, but type I IFN transcription is inhibited by DA L (35) . Of note, abnormalities in translation underlie nonviral causes of demyelination, such as those involving ER stress (which can lead to a block in translation) in inherited demyelinating diseases (17, 32, 40) . Myelinsynthesizing cells may be especially vulnerable to translational abnormalities because of the large amount of membrane protein that needs to be synthesized by these cells.
It is of interest that DAL/Cre mice had prominent peripheral nerve demyelination with Schwann cell degeneration, presumably because DA L was expressed in Schwann cells (as well as oligodendrocytes). These abnormalities may have led to the paralysis and subsequent death of mice treated early with tamoxifen. Although peripheral nerve pathology is not a feature of mice infected intracerebrally with DA virus, intrasciatic nerve injection with DA virus is known to cause peripheral nerve demyelination (8) . The peripheral nerve disease in tamoxifen-treated DAL/Cre (and DA/Cre) transgenic mice tended to be more prominent than the CNS disease; for example, there were more cells that had prominent activated caspase-3 antibody staining in the nerve roots (Fig. 3E ) than in the spinal cords of moribund tamoxifen-treated DAL/Cre mice (Fig. 3F) . The finding of greater pathology in the PNS than the CNS contrasts with findings in two recent studies in mice that carried a transgene similar or identical to PLP/CreER T (22, 38) . In these studies, which involved inducible and myelinsynthesizing cell-specific expression of the diphtheria toxin A subunit, disease of the white matter of the CNS was prominent, with little or no mention of pathology in the PNS. The greater pathology in the PNS seen in DAL/Cre mice may relate to the use in our study of a lower dosage of tamoxifen (allowing for greater recombination in the periphery). It may also be that DAL/Cre mice died before the bulk of CNS white matter pathology became apparent since the reaction to injury by peripheral nerves is greatly accelerated compared to that found in oligodendrocytes (42) . This possibility garners support from our finding of prominent CNS demyelination in tamoxifen-treated mice that partly recovered and were sacrificed 26 days following the onset of significant weakness (Fig.  4 to 6) .
Although some tamoxifen-treated DAL/Cre mice had prominent CNS demyelination (Fig. 4 to 6) , the demyelination differed from that seen in TMEV-IDD. Tamoxifen-treated DAL/ Cre mice had scattered demyelinated axons, presumably because the Cre-induced recombination randomly occurred in myelin-synthesizing cells. In contrast, demyelinated areas in mice with TMEV-IDD are well-demarcated regions, perhaps related to the spread of virus. Tamoxifen-treated DAL/Cre mice with prominent CNS demyelination had more demyelination in the optic nerves and brain than the spinal cord, presumably because the activity of the PLP gene transcription control region driving Cre varies in location depending on the age of the mouse (16) . In contrast, the brunt of the white matter disease in the case of TMEV-IDD is in the spinal cord, presumably as a result of the intracerebral inoculation of virus followed by trafficking of the virus. It may also be that the demyelination in tamoxifen-treated DAL/Cre mice differs from TMEV-IDD because T cells are present in the lesions in TMEV-IDD, but not in DAL/Cre mice. Abnormalities of T cells, including T regulatory cells (24) and Th17 cells (14) , play a role in TMEV persistence and disease pathogenesis. In addition, a persistent TMEV infection of microglia is important in initiating of immune responses, including a myelin-specific immune response (21) , and in generating a proinflammatory immune response (13) . Furthermore, L* protein, which is initiated in the L-coding region and is out of frame with the polyprotein, is important for efficient growth of TMEV in microglia (37) and in antagonizing the antivirus immune response (reviewed in reference 20).
Our findings bring up the possibility that other demyelinating diseases, and perhaps MS, may also be associated with direct oligodendrocyte dysfunction from a pathogen. Of note, oligodendrocyte death and apoptosis in the absence of T cell infiltration have been reported to be an early feature of MS (12) . Furthermore, a recent genomics study of MS identified the apoptotic regulator gene BCL2 as important for susceptibility (44) .
